PRENOXAD

This brand name is authorized in Australia, Estonia, France, Ireland, UK.

Active ingredients

The drug PRENOXAD contains one active pharmaceutical ingredient (API):

1	Naloxone UNII F850569PQR - NALOXONE HYDROCHLORIDE
	Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine.
	Read more about Naloxone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PRENOXAD Solution for injection/infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AB15	Naloxone	V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AB Antidotes
Discover more medicines within V03AB15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11077B, 11078C
EE	Ravimiamet	1626498, 1670161
FR	Base de données publique des médicaments	62968616
GB	Medicines & Healthcare Products Regulatory Agency	223438